Poor
Mostly Aligned
Patient Risk:
Moderate
Summary
Overall, the claims largely diverge from the FDA-approved label. Several asserted percentages for liver enzyme elevations are not supported by the label's data; some assertions are unsubstantiated or not quantified in the label. Notable safety content (e.g., boxed warning, hepatic impairment dosing, monitoring recommendations) is not adequately addressed by the claims.
Category Scores
Accurate Statements
Abnormalities mainly involved AST/ALT rises.
Table 1 shows SGOT Increased 4% and SGPT Increased 5% for TIGACIL, with comparator rates around 4–5%; AST/ALT elevations are the documented liver enzyme abnormalities in the clinical trial data.
Unsupported Statements
In pivotal phase 3 trials for cSSSI and cIAI, 14.6% of tigecycline-treated patients experienced elevated liver enzymes (primarily AST/ALT >3x upper limit of normal), compared to 10.3% on comparators.
Label indicates single-digit elevations (SGOT ~4%, SGPT ~5%) in TIGACIL vs comparators; 14.6% and 10.3% are not reflected in the label data.
In cSSSI trials, Tigecycline 15.3% vs. vancomycin 12.3% experienced elevated liver enzymes.
Label data show single-digit elevations (SGOT/SGPT) with no such 15.3% vs 12.3% figures.
In cIAI trials, Tigecycline 14.0% vs. imipenem/cilastatin 9.3% experienced elevated liver enzymes.
Label data show single-digit elevations with comparator rates not in the 9.3–14.0% range.
Pooled analysis across 13 trials showed similar imbalances, with tigecycline at ~15% for transaminase elevations.
Label data indicate transaminase elevations in single-digit percentages; no ~15% pooled figure is provided.
Discontinuation due to liver issues occurred in 0.5-1% of tigecycline patients vs 0.4% on comparators.
Label reports discontinuation due to adverse reactions as 7% vs 6% for comparators; organ-specific discontinuation rates (e.g., liver) are not provided.
Post-marketing reports note higher risks in hepatic impairment patients.
Postmarketing section lists hepatic AEs but does not quantify higher risk specifically in patients with hepatic impairment.
Patients with pre-existing liver disease or on hepatotoxic drugs see elevated rates up to 20-25%.
Label does not provide such stratified rate data (20–25%) for these subgroups.
Tigecycline's biliary excretion contributes to liver enzyme elevations; monitor LFTs closely, especially in the first weeks.
No explicit statement in the provided sections links biliary excretion to LFT elevations or prescribes early-week monitoring; not supported by the excerpts.
Liver enzyme elevations with tigecycline are higher than beta-lactams (e.g., 9-12% for carbapenems) but similar to some glycylcyclines or vancomycin in polymicrobial settings.
Label provides specific single-digit rates and comparator data; no 9–12% carbapenem figure or glycylcycline/vanc data in this context.
Contradictions
Low
AI Statement
In pivotal phase 3 trials for cSSSI and cIAI, 14.6% of tigecycline-treated patients experienced elevated liver enzymes (primarily AST/ALT >3x ULN), compared to 10.3% on comparators.
Label Reference
6.1
Low
AI Statement
In cSSSI trials, Tigecycline 15.3% vs. vancomycin 12.3% experienced elevated liver enzymes.
Label Reference
6.1
Low
AI Statement
In cIAI trials, Tigecycline 14.0% vs. imipenem/cilastatin 9.3% experienced elevated liver enzymes.
Label Reference
6.1
Low
AI Statement
Pooled analysis across 13 trials showed similar imbalances, with tigecycline at ~15% for transaminase elevations.
Label Reference
6.1
Important Omissions
Boxed warning regarding all-cause mortality is not discussed in the claims.
Importance:
Critical
Dosing adjustments for hepatic impairment (including severe impairment) are not addressed in the claims.
Importance:
Critical
Monitoring recommendations and explicit postmarketing signals related to hepatic safety are not fully addressed.
Importance:
Moderate
Pregnancy risk/pediatric safety data from the label are not addressed by the claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
LFT elevations are reported in single-digit percentages; however, the label contains a boxed mortality risk warning and hepatic adverse effects in postmarketing data, indicating a non-negligible safety consideration.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Overstatement and misquoting of liver enzyme elevation rates; lack of coverage of boxed mortality warning and hepatic impairment dosing; several major safety content omissions.
Suggested Improvement
Align claims to label: report exact LFT elevations (SGOT ~4%, SGPT ~5%), note Boxed Warning; provide hepatic impairment dosing guidance; specify monitoring recommendations and postmarketing safety signals; avoid unsupported percentage claims.